The Algerian pharmaceutical group Saidal has signed a Memorandum of Understanding (MoU) with a Libyan delegation aimed at revitalising and developing bilateral cooperation in the pharmaceutical industry between Algeria and Libya.
The signing ceremony took place at Saidal’s headquarters on Sunday, 5 October 2025, in the presence of Nabila Benygzer Ouaret, Chairwoman and CEO of the Saidal Group, and Akram Ali Ahmed Al-Saeed, Director General of Al-Louloua Al-Oula Company for the Import of Medicines and Medical Products. Several senior executives from Saidal also attended the event.
The agreement focuses on relaunching Saidal’s pharmaceutical exports to the Libyan market, alongside transferring expertise and technology in the field of pharmaceutical production. This partnership is expected to strengthen Libya’s access to essential medicines and support the development of its local pharmaceutical capabilities.
The initiative is part of the ongoing momentum inspired by the Intra-African Trade Fair (IATF), which promotes regional integration and economic cooperation across the continent. Both Algeria and Libya have expressed their mutual commitment to enhancing bilateral relations and boosting economic exchanges, particularly in healthcare and manufacturing sectors.
Through this MoU, Saidal aims to expand its footprint in North Africa while contributing to Libya’s healthcare resilience. The collaboration also highlights both nations’ shared vision to foster sustainable development and advance the African pharmaceutical industry.
Officials from both sides described the signing as a significant milestone in strengthening South-South cooperation, with a focus on health sovereignty, innovation, and the exchange of scientific expertise between Algeria and Libya.
